Shripad Banavali from the Department of Medical and Pediatric Oncology, Tata Memorial Centre, in India; Eddy Pasquier from the Aix Marseille Université, Inserm, CRO2 UMR_S 91, Marseille France and Nicolas André from the Service d’Hématologie & Oncologie Pédiatrique, AP-HM in Marseille France and all members of MGHI have just published a case report entitled "Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma" in ecancermedicalscience the open access cancer journal from the European Institute of Oncology and the OECI, further confirming the potential use of metronmics combinations for paitents living in both high and middle and low income countries.
The abstract is pasted bellow and the full text is available as and attached file or in free access here.
We report here a case of a 69-year-old woman with a relapsing metastatic angiosarcoma treated with a combination of metronomic chemotherapy and propranolol. The beta blockers were added since the tumour was positive for beta-adrenergic receptor. A complete response was quickly obtained and lasted for 20 months.
With this case, the combination of metronomic chemotherapy and propranolol in angiosarcoma warrants additional studies and illustrates the potential of metronomics to generate innovative yet inexpensive targeted therapies for both high-income and low-/middle-income countries.